Abstract
The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) increases the need for a rapid development of efficient vaccines. Among other vaccines in clinical trials, a recombinant VSV-∆G-spike vaccine was developed by the Israel Institute for Biological Research (IIBR) and is being evaluated. The development of an efficient downstream purification process (DSP) enables the vaccine to be advanced to clinical trials. The DSP must eliminate impurities, either process- or product-related, to yield a sufficient product with high purity, potency and quality. To acquire critical information on process restrictions and qualities, the application of in-line monitoring is vital and should significantly impact the process yield, product quality and economy of the entire process. Here, we describe an in-line monitoring technique that was applied in the DSP of the VSV-∆G-spike vaccine. The technique is based on determining the concentrations of metabolites, nutrients and a host cell protein using the automatic chemistry analyzer, Cobas Integra 400 Plus. The analysis revealed critical information on process parameters and significantly impacted purification processes. The technique is rapid, easy and efficient. Adopting this technique during the purification process improves the process yield and the product quality and enhances the economy of the entire downstream process for biotechnology and bio pharmaceutical products.
Highlights
IntroductionCoronavirus disease (COVID-19) is an infectious disease caused by Severe Acute
Coronavirus disease (COVID-19) is an infectious disease caused by Severe AcuteRespiratory Syndrome Coronavirus 2 (SARS-CoV-2) and mainly comprises symptoms in the lungs, causing cough and fever [1]
Sample analysis from all the purification steps with clarification the chemistry analyzer revealedChromatography critical information on process parameters and attributes
Summary
Coronavirus disease (COVID-19) is an infectious disease caused by Severe Acute. Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and mainly comprises symptoms in the lungs, causing cough and fever [1]. As of November 2021, more than 300 vaccines are in clinical and pre-clinical trials, all targeting the spike protein of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). One of the vaccines being tested in clinical trials is being developed by the IIBR [3,4]. This vaccine is based on the vesicular stomatitis virus (VSV), in which the VSV-G protein has been replaced with the SARS-CoV-2 spike protein (rVSV-∆G-spike), creating a recombinant replicating virus [3,4,5]. The virus is released into the culture medium and, at the end of the production process, the medium is collected
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.